BPC-157

Home › Research › BPC-157

View BPC-157 in the AxYn range →

Snapshot

Chemistry and make-up

A 15-residue linear peptide, proline-rich, no cysteine (so no disulfide bridges) and no metal binding. That proline content is part of why it is described as unusually stable in gastric-acid-like conditions [A]. Sold as free base, acetate, or arginate salt. The salt/counterion changes the molecular weight and solubility, which is exactly why the CoA must state the form and the observed mass, not just “BPC-157”. The FDA has flagged that “BPC-157” is a common name, not a USAN, and that multiple salts and derivatives ship under the same label, which it treats as a safety/identity risk [B].

What it is studied for (evidence)

• Mechanism (preclinical [A]): activates VEGFR2 and the Akt-eNOS nitric-oxide axis, driving angiogenesis; promotes fibroblast activity, collagen synthesis, and cell migration; up-regulates the growth hormone receptor in tendon fibroblasts (dose- and time-dependent, mRNA and protein) (Chang et al., PMC6271067). Accelerates healing of transected rat Achilles tendon and rat ligament in vitro/in vivo (PubMed 21030672).
• Established: a large, consistent rodent body of evidence for tendon, ligament, muscle, bone and GI repair and cytoprotection (Narrative review, Curr Rev Musculoskelet Med 2025) [A].
• Emerging / thin: human evidence is very limited. A 2025 systematic review of 36 studies (1993-2024) found only 1 clinical study among them; the rest preclinical (PubMed 40756949) [A]. A 2025 IV safety/PK pilot in 2 healthy adults (10 and 20 mg) reported no serious adverse events with plasma returning to baseline within 24 h [A/D — small pilot]. No randomised placebo-controlled efficacy trial has been completed and published for any indication.
• Single-group caveat: the majority of the primary literature originates from one laboratory (Prof. Predrag Sikiric, University of Zagreb), with a growing but still limited set of independent replications [A]. Weight the evidence accordingly.
• Marketing claims vs data: vendor pages routinely present rodent findings and dosing protocols as if human-established. They are not. Treat all “heals X in humans” and any dosing as unsupported extrapolation.

Handling, format and stability

Supplied lyophilised; reconstituted with bacteriostatic water for research handling (no dosing guidance here). Store lyophilised cold and protected from light; reconstituted peptide is less stable and cold-chain dependent. The arginate salt is promoted for better aqueous solubility and handling stability versus free base. FDA reviewers noted most BPC-157 acetate CoAs contain purity testing only and lack impurity/safety characterisation (nitrosamines, mutagenic/teratogenic impurities) [B] — a prompt for buyers to demand fuller CoAs than the market norm.

Regulatory and trade status

• UK/EU RUO: research use only; not an approved medicine. Marketing language that claims healing/treatment can pull it into “medicinal product by presentation” territory, so keep listings and emails strictly RUO.
• US (bellwether): long treated as off-limits for pharmacy compounding (interim 503A Category 2, “red light”). In April 2026 BPC-157 (free base and acetate) was removed from Category 2 and referred to the Pharmacy Compounding Advisory Committee, and on 23 July 2026 the PCAC voted 8 to 6 (1 abstention) to recommend BPC-157 for the 503A bulks list, over the objection of FDA scientific staff (FDA meeting, briefing doc) [B]. This is an advisory recommendation only, not a rule: adding it to the bulks list still requires FDA rulemaking (realistically into 2027), and FDA has overridden PCAC before. Worth tracking, but nothing has changed the sale-as-RUO position in the UK.
• WADA (sport): prohibited at all times under S0 (non-approved substances), as an experimental peptide with no approval for human therapeutic use. USADA names BPC-157 explicitly as an S0 substance (USADA) [B].
• Customs: lower profile than the GLP-1 class, but the identity/salt ambiguity is the main trade risk.

Sources

• [A] Narrative review, *Curr Rev Musculoskelet Med* 2025 — https://link.springer.com/content/pdf/10.1007/s12178-025-09990-7.pdf
• [A] “From Regeneration to Analgesia”, *IJMS* 2026 (PMC13026520) — https://pmc.ncbi.nlm.nih.gov/articles/PMC13026520/
• [A] Systematic review, orthopaedic sports medicine (PubMed 40756949) — https://pubmed.ncbi.nlm.nih.gov/40756949/
• [A] GH receptor in tendon fibroblasts (PMC6271067) — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6271067/
• [A] Achilles tendon healing (PubMed 21030672) — https://pubmed.ncbi.nlm.nih.gov/21030672/
• [B] FDA PCAC 23-24 July 2026 meeting + briefing (BPC-157 recommended 8-6) — https://www.fda.gov/media/193343/download
• [B] USADA, BPC-157 prohibited under WADA S0 — https://www.usada.org/spirit-of-sport/bpc-157-peptide-prohibited/
• [B] FDA 503A bulk drug substances — https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
• [B] PubChem CID 9941957
• [D] Vendor/clinic blogs (Irvine Health, Peptide-DB, PeptidesInsider) — commercial; they publish dosing, which we do not use.

Plain summary

BPC-157 is a 15-amino-acid repair peptide with a large and fairly consistent animal evidence base for tendon, muscle and gut healing, driven mainly by one research group, but almost no human trial evidence yet. Commercially the biggest trap is identity: free base vs acetate vs arginate all ship as “BPC-157”, so AxYn’s CoAs must state the salt form, the observed mass, and ideally an impurities panel, because regulators (FDA) have singled out this peptide’s thin CoAs as a concern.

For laboratory and research use only (RUO). Not for human or veterinary use, not for consumption, and not a medicine. Information is a research summary, not medical advice, and contains no dosing guidance.

For laboratory research use only. Not for human or veterinary use, not for consumption, and not a medicine. This is a research summary, not medical advice, and contains no dosing guidance.